Teva and Intel partner to tackle Huntington’s disease

Recent news indicate that Teva Pharmaceutical Industries Ltd is now partnering with the Intel Corp, as they aim to develop the wearable technology platform that would be able to track the progression of diseases in patients who have Huntington’s disease.

Huntington’s is a degenerative disease, and is a fatal disorder. The condition is inherited and is known to cause a progressive breakdown of the nerve cells in the brain, which normally results in he gradual decline of the motor control of the patient. The cognition and mental ability of the patient also decreases.

Alteration of the course of Huntington’s disease and medications are unknown, though there are some certain drugs which help with the symptoms part of the disease. After 15-25 years with the disease patients usually succumb to the disease.

The new partnership of Teva and Intel will see Teva start deploying the technology they are creating as part of their ongoing mid stage Huntington’s study. The Israeli based company announced the news on Thursday. Patients will be able to make use of their smartphones and their smartwatches to sense the technology and then continuously measure for the functioning and the movement of the technology.

The data which will be extrapolated from the devices is then going to streamed wirelessly from the cloud based platform, which would develop into Intel. The data will be translated by the device and will be in near real time and put in scores so that they can assess the motor symptom severity of the patient.

There once was a line between pharmaceuticals and technology, but it seems now and again that line is slowly diminishing and the two sectors are now being forced to join hands so as to combat the chronic diseases out there by combining their biology, software and hardware. The monitoring of the wearables is in the future expected to rise as companies offer value based healthcare.

The aim of the mission is to prove that the medicines in use can keep large scores of people healthy at any given time. This would help improve the appeal to the cost conscious carriers. The move would give the drugmakers one major incentive as they look to offer their services to the people and aim to get it go beyond the usual routine drug prescriptions.

Tech giants such as Apple, Samsung and Alphabet, have all been looking at ways they could improve the health related applications, as they look to put new wearable products.

This is the second partnership that Teva has joined with a technology company after announcing another one with IBM last year.